论文部分内容阅读
目的:探讨芪苈强心胶囊不同联用方案治疗慢性心力衰竭的效果。方法:抽取2019年1月至2019年12月长治市第三人民医院收治的慢性心力衰竭患者305例，依据掷硬币法分为两组。观察组155例采用芪苈强心胶囊联合沙库巴曲缬沙坦治疗，对照组150例采用芪苈强心胶囊联合缬沙坦治疗，连续治疗10周。比较两组临床疗效、心功能指标及相关实验室指标。结果:治疗10周，观察组总有效率(91.61%，142/155)高于对照组(79.33%，119/150)。治疗10周，两组左心室射血分数、每搏输出量高于治疗前，且观察组高于对照组(n t＝8.100、12.362，n P＝0.001、0.001)；两组血清脑钠肽、基质金属蛋白酶-9水平低于治疗前，且观察组低于对照组(n t＝13.574、4.904，n P＝0.001、0.001)。观察组不良反应发生率(5.81%，9/155)与对照组(6.67%，10/150)比较，差异未见统计学意义(n P>0.05)。n 结论:芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭效果更佳，有助于改善患者心功能指标及实验室指标，且不会增加不良反应。“,”Objective:To investigate the effects of different combination regimens of qiliqiangxin capsule on chronic heart failure.Methods:A total of 305 patients with chronic heart failure admitted to Changzhi Third People’s Hospital from January 2019 to December 2019 were divided into two groups according to the coin tossing method. One hundred and fifty-five cases in the observation group were treated with qiliqiangxin capsules combined with sarkubatur valsartan, and 150 cases in the control group were treated with qiliqiangxin capsules combined with valsartan for 10 weeks, they were treated continuously for 10 weeks. The clinical efficacy, cardiac function indicators and related laboratory indicators were compared between the two groups.Results:After 10 weeks of treatment, the total effective rate of the observation group (91.61%, 142/155) was higher than that of the control group (79.33%, 119/150). After 10 weeks of treatment, the left ventricular ejection fractionand stroke volume of the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (n t=8.100, 12.362, n P=0.001, 0.001); the levels of serum brain natriuretic peptide and matrix metalloproteinase-9 in the group were lower than those before treatment, and those in the observation group was lower than those in the control group (n t=13.574, 4.904, n P=0.001, 0.001). The incidence of adverse reactions in the observation group (5.81%, 9/155) was compared with that in the control group (6.67%, 10/150), n P>0.05.n Conclusions:Chronic heart failure patients with qiliqiangxin capsule combined with shakubatur valsartan treatment effect is better, and help to improve the patient’s heart function indicators and laboratory indicators, and will not increase adverse reactions.